Source:http://linkedlifedata.com/resource/pubmed/id/20414041
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2010-4-23
|
pubmed:abstractText |
Malignant transformation of an ovarian mature cystic teratoma is very rare; it arises in about 1-2% of all dermoid cysts. No standard treatment has been established for advanced and recurrent disease. In Case 1, a 78-year-old woman was diagnosed with squamous cell carcinoma arising from a mature cystic teratoma of the ovary after undergoing right salpingo-oophorectomy (RSO). She was treated with chemotherapy(TC), but the carcinoma recurred 2 months after completing first-line chemotherapy. She began second-line chemotherapy (PEC: CBDCA+PEP+etoposide), but became disoriented on the second day of treatment, and could not complete the schedule. She died 2 months after the recurrence. Case 2 was a 60-year-old woman diagnosed with stage Ic disease when she underwent a computed tomography scan during chemotherapy for breast cancer recurrence in her liver. She underwent bilateral salpingo-oophorectomy (BSO), and was treated with chemotherapy (TC+trastuzumab). She received 5 courses, but the breast cancer metastases enlarged and her chemotherapy regimen was changed. Five months later, after completing 5 courses of TC+trastuzumab, she had disseminated recurrence in the pelvis and also had a mass. She developed ileus and underwent a colostomy. She then underwent transcatheter arterial embolization via the inferior mesenteric artery and received cisplatin (100 mg/body) as second-line chemotherapy. The tumor was reduced in size about 30%, for a partial remission. However, her breast cancer recurrence was exacerbated and she died. The results of TAE, however, showed that it may be an effective second-line therapy for recurrent squamous cell carcinoma arising from a mature cystic teratoma.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
747-52
|
pubmed:meshHeading |
pubmed-meshheading:20414041-Aged,
pubmed-meshheading:20414041-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20414041-Carboplatin,
pubmed-meshheading:20414041-Carcinoma, Squamous Cell,
pubmed-meshheading:20414041-Drug Resistance, Multiple,
pubmed-meshheading:20414041-Drug Resistance, Neoplasm,
pubmed-meshheading:20414041-Fatal Outcome,
pubmed-meshheading:20414041-Female,
pubmed-meshheading:20414041-Humans,
pubmed-meshheading:20414041-Middle Aged,
pubmed-meshheading:20414041-Neoplasm Staging,
pubmed-meshheading:20414041-Ovarian Neoplasms,
pubmed-meshheading:20414041-Ovariectomy,
pubmed-meshheading:20414041-Paclitaxel,
pubmed-meshheading:20414041-Palliative Care
|
pubmed:year |
2010
|
pubmed:articleTitle |
[Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary].
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Shimane University School of Medicine.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|